source
- STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategyMedical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
- Novartis reports nine cancer cases in patients treated with Zolgensma gene therapyNovartis disclosed that nine individuals with spinal muscular atrophy who received its gene therapy Zolgensma later developed tumors. Two of the cases showed evidence that the adeno-associated vir…